New research out of VCU Massey Comprehensive Cancer Center provides promising evidence for an innovative combination treatment strategy that uses cells’ waste removal functions to effectively dismantle multiple myeloma. The findings, published recently in Cell Death & Disease, show how an experimental targeted protein degrader, developed in-house at the cancer center, enhances the destruction of a specific cancer cell survival protein and works in tandem with existing drugs in preclinical models, while showing limited toxicity in cardiac models.

A new study from the Medical University of South Carolina shows that In Our DNA SC, a community genomic screening program, has successfully reached participants in all 46 South Carolina counties, including many rural and medically underserved communities. More than 50,000 adults have enrolled in the no-cost program, which screens for inherited genetic variants linked to hereditary breast and ovarian cancer syndrome, Lynch syndrome and familial hypercholesterolemia. About one in 65 participants has been identified as having a higher-risk genetic variant and is offered genetic counseling and preventive follow-up care.

Published in JAMA Network Open, the study found that combining flexible testing options, including clinic visits, community events and at-home kits, with strong community partnerships helped to expand access to genomic screening beyond traditional health care settings. Researchers say the program not only improves access to early disease prevention but also helps to ensure that South Carolinians from diverse geographic and socioeconomic backgrounds are represented in genomic research. The next phase of the project will examine whether this broad reach leads to increased use of preventive care and ultimately reduces the burden of cancer and heart disease across the state.

Scientists have developed a new method for accurately predicting gene changes that cause lung cancer, without the need for slower, more expensive lab techniques.